FULC
Fulcrum Therapeutics, Inc.·Healthcare
7.55
4.551%(−0.36)
Market ClosedLast Updated: — ET
52W L: $2.7152W H: $15.74
FULC NEWS
defenseworld.net
Apr 4
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of “Moderate Buy” by Brokerages
Fulcrum Therapeutics, Inc. (NASDAQ: FULC - Get Free Report) has received an average rating of "Moderate Buy" from the ten research firms that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the
globenewswire.com
Mar 19
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
Three-year collaboration is aimed at enhancing a key aspect of sickle cell management: expediting care during a pain crisis Three-year collaboration is aimed at enhancing a key aspect of sickle cell management: expediting care during a pain crisis
defenseworld.net
Mar 10
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of “Moderate Buy” by Analysts
Shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC - Get Free Report) have earned an average recommendation of "Moderate Buy" from the ten research firms that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating
globenewswire.com
Mar 6
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to one new employee.
globenewswire.com
Mar 3
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the Leerink Partners Global Healthcare Conference in Miami, FL on Tuesday, March 10, 2025 at 1:00 p.m.
seekingalpha.com
Feb 26
Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion
Fulcrum Therapeutics (FULC) pivots to pociredir for severe sickle cell disease after discontinuing losmapimod. Pociredir's Phase 1 PIONEER data shows 7/12 patients hitting the ≥20% HbF threshold, but mean HbF just misses the mark. FULC's valuation is tied almost entirely to pociredir, with a risk-adjusted NPV of $136 million and $352.3 million in cash.
